Post-approval studies (Phase 4)Active Not RecruitingNCT03229200
What this trial is testing
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Who this might be right for
Lymphoma, B-CellLymphoma, Non-HodgkinLeukemia, B-cell+2 more
Pharmacyclics Switzerland GmbH 297